Beijing Grand Johamu Pharmaceutical Co., Ltd.

Beijing Grand Johamu Pharmaceutical Co., Ltd. (北京远大九和药业有限公司), often shortened to Grand Johamu (远大九和) and branded internationally as Johamu, is a Chinese pharmaceutical company founded in 2003. It is a national and Zhongguancun dual high-tech enterprise. Its headquarters and manufacturing plant are located in Doudian, Fangshan District, Beijing, covering 52.4 mu (about 3.5 hectares) with a building area of 23,806 square meters. In July 2015, the company became a controlled subsidiary of Grand Pharma (远大医药集团有限公司) and is responsible for Grand Pharma's respiratory and critical care business both in China and internationally. As one of Grand Pharma's core strategic segments, Grand Johamu markets products covering rhinitis, bronchitis, pneumonia, asthma, and chronic obstructive pulmonary disease (COPD), forming a relatively complete product portfolio in respiratory disease treatment. Its core product, Qienuo (切诺), an eucalyptol, limonene and pinene enteric capsule, is a mucus-dissolving expectorant recommended by multiple guidelines and expert consensus. The company also offers two globally innovative combination asthma products, Enerzair Breezhaler (恩卓润) and Atectura Breezhaler (恩明润), which entered China's National Reimbursement Drug List (NRDL) in January 2023. In 2024, the company acquired Nanchang Baiji Pharmaceutical (renamed Grand Johamu (Jiangxi) Pharmaceutical Co., Ltd.), expanding its upper airway disease pipeline with first-line drugs such as budesonide nasal spray and fluticasone propionate nasal spray. The company upholds the corporate spirit of "dare to be first, share success" and the management philosophy of "provide good products, cultivate a high realm." It aims to become a pharmaceutical enterprise respected by doctors and patients and to give back to society. Grand Johamu operates two advanced soft capsule production lines with an annual capacity of 1.25 billion capsules. Its main product, eucalyptol, limonene and pinene enteric capsules (brand name Qienuo), is a self-developed national Class 3 new drug. The company has seven production lines, three of which have passed GMP certification, with the other four used for new product development. It invests no less than 4% of sales revenue annually in new product development and has obtained 34 authorized patents, including 20 valid invention patents. It was recognized as a Beijing Intellectual Property pilot unit in February 2019, a Beijing Intellectual Property demonstration unit in December 2019, and a National Intellectual Property Advantage Enterprise in 2022. The company is committed to building a well-known brand in the respiratory field, focusing on full-cycle chronic airway disease management and critical infection product pipelines.

Beijing Grand Johamu Pharmaceutical Co., Ltd. was founded in 2003. In 2004, its raw material drug workshop and oral solid preparation workshop passed national GMP certification in one go. In 2005, the adult specification of eucalyptol, limonene and pinene enteric capsules obtained a drug registration approval and new drug certificate. In 2013, the company was recognized as a Beijing high-tech enterprise, and its hard capsules, soft capsules, and raw materials passed the new version of GMP certification. In July 2015, Grand Pharma (China) acquired a 97% equity stake, making the company a controlled subsidiary of Grand Pharma, and it was renamed Beijing Grand Johamu Pharmaceutical Co., Ltd. In 2017, eucalyptol, limonene and pinene enteric capsules entered the 2017 National Reimbursement Drug List (NRDL). In 2018, taxes paid exceeded 100 million yuan, and profits exceeded 100 million yuan. In 2019, the company obtained the Intellectual Property Management System certification, was recognized as an intellectual property pilot, demonstration, and compliance certification unit, and eucalyptol, limonene and pinene entered the National Essential Medicines List. In 2020, the company celebrated its 2020-2025 strategic planning, marketing model transformation, and the establishment of an OTC e-commerce platform. In 2021, the product "eucalyptol, limonene and pinene enteric soft capsules" was renamed "eucalyptol, limonene and pinene enteric capsules," and the company obtained Class II medical device business filing qualification. In 2022, the company was awarded the title of Beijing "Specialized, Refined, Distinctive, and Innovative" SME; on September 3, 2022, Enerzair and Atectura were officially launched in China; the company gained access to two national respiratory medicine centers; and it established Beijing Grand Changsheng Pharmaceutical Sales Co., Ltd. with GSP qualification. In 2023, Enerzair and Atectura (three specifications) were listed in the 2022 National Reimbursement Drug List; the company achieved clean production and green factory creation; and the overseas production site transfer for the "dual En" products was approved. In 2024, the company completed the acquisition of Nanchang Baiji (now renamed Grand Johamu (Jiangxi) Pharmaceutical Co., Ltd.), achieving layout in the upper airway product pipeline. Throughout its history, the company has focused on respiratory diseases and has built a comprehensive product portfolio covering rhinitis, bronchitis, pneumonia, asthma, and COPD.

• 2024

  Completed acquisition of Nanchang Baiji (renamed Grand Johamu (Jiangxi) Pharmaceutical Co., Ltd.), expanding upper airway product pipeline.

• 2023

  Enerzair and Atectura (three specifications) listed in 2022 National Reimbursement Drug List; achieved clean production and green factory creation; overseas production site transfer for "dual En" products approved.

• 2022

  Awarded Beijing "Specialized, Refined, Distinctive, and Innovative" SME; Enerzair and Atectura launched in China on September 3; access to two national respiratory medicine centers; established Beijing Grand Changsheng Pharmaceutical Sales Co., Ltd. with GSP qualification.

• 2021

  "Eucalyptol, limonene and pinene enteric soft capsules" renamed "eucalyptol, limonene and pinene enteric capsules"; obtained Class II medical device business filing qualification.

• 2020

  2020-2025 strategic planning; marketing model transformation; OTC e-commerce platform established.

• 2019

  Obtained Intellectual Property Management System certification; recognized as intellectual property pilot, demonstration, and compliance unit; eucalyptol, limonene and pinene entered National Essential Medicines List.

• 2018

  Taxes paid exceeded 100 million yuan; profits exceeded 100 million yuan.

• 2017

  Eucalyptol, limonene and pinene enteric soft capsules entered the 2017 National Reimbursement Drug List.

• 2015

  Grand Pharma (China) acquired 97% equity; company became a controlled subsidiary and was renamed Beijing Grand Johamu Pharmaceutical Co., Ltd.

• 2013

  Recognized as Beijing high-tech enterprise; hard capsules, soft capsules, and raw materials passed new GMP certification.

• 2005

  Adult specification of eucalyptol, limonene and pinene enteric capsules obtained drug registration approval and new drug certificate.

• 2004

  Raw material drug workshop and oral solid preparation workshop passed national GMP certification.

• 2003

  Company founded.

A respiratory-focused pharmaceutical enterprise under Grand Pharma, dedicated to full-cycle chronic airway disease management and critical infection products, aiming to be respected by doctors and patients.

• Eucalyptol, Limonene and Pinene Enteric Capsules (Qienuo)

  Mucus-dissolving expectorant for acute and chronic bronchitis, pneumonia, bronchiectasis, lung abscess, COPD, pulmonary fungal infection, tuberculosis, and silicosis.

• Indacaterol/Glycopyrronium/Mometasone Furoate Inhalation Powder (II) (Enerzair Breezhaler)

  Fixed triple combination inhaler for asthma, once-daily, rapid onset within 5 minutes, 24-hour control.

• Indacaterol/Mometasone Furoate Inhalation Powder (II) (Atectura Breezhaler)

  Once-daily dual combination inhaler for asthma, rapid onset within 5 minutes, 24-hour control.

• Indacaterol/Mometasone Furoate Inhalation Powder (III) (Atectura Breezhaler)

  Once-daily dual combination inhaler for asthma, rapid onset within 5 minutes, 24-hour control.

• Fluticasone Propionate Nasal Spray (Qienuo)

  First fluticasone propionate nasal spray in China to pass consistency evaluation; national reimbursement and essential medicines list product.

• Budesonide Nasal Spray

  First-line treatment for upper airway inflammatory diseases, introduced through the acquisition of Nanchang Baiji.

1. 1首页_北京远大九和药业有限公司bjjiuhe.com
2. 2企业简介_远大九和_北京远大九和药业有限公司bjjiuhe.com
3. 3大事记_远大九和_北京远大九和药业有限公司bjjiuhe.com
4. 4领导致辞_远大九和_北京远大九和药业有限公司bjjiuhe.com
5. 5北京远大九和药业有限公司 - Wikidatawikidata.org